KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Common Equity (2016 - 2025)

Historic Common Equity for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to -$156.7 million.

  • Novavax's Common Equity rose 7023.91% to -$156.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$156.7 million, marking a year-over-year increase of 7023.91%. This contributed to the annual value of -$623.8 million for FY2024, which is 1298.4% up from last year.
  • Per Novavax's latest filing, its Common Equity stood at -$156.7 million for Q3 2025, which was up 7023.91% from $37.6 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Common Equity ranged from a high of $1.0 billion in Q1 2021 and a low of -$895.6 million during Q1 2023
  • Moreover, its 5-year median value for Common Equity was -$431.7 million (2024), whereas its average is -$281.4 million.
  • As far as peak fluctuations go, Novavax's Common Equity soared by 443493.39% in 2021, and later crashed by 147098.46% in 2023.
  • Novavax's Common Equity (Quarter) stood at -$351.7 million in 2021, then tumbled by 80.3% to -$634.1 million in 2022, then decreased by 13.07% to -$716.9 million in 2023, then rose by 12.98% to -$623.8 million in 2024, then soared by 74.89% to -$156.7 million in 2025.
  • Its Common Equity stands at -$156.7 million for Q3 2025, versus $37.6 million for Q2 2025 and -$75.6 million for Q1 2025.